A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer
Computational and Systems Oncology · 2021
DOI: 10.1002/cso2.1019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computational and Systems Oncology, 2021. Verfasst von Kamaldeen Okuneye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Applied BioMath, LLC, Concord, Massachusetts, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Bladder cancer is a common malignancy with over 80,000 estimated new cases and nearly 18,000 deaths per year in the United States alone. Therapeutic options for metastatic bladder cancer had not evolved much for nearly four decades, until recently, when five immune checkpoint inhibitors were approved by the U.S. Food and Drug Administration (FDA). Despite the activity of these drugs in some patients, the objective response rate for each is less than 25%. At the same time, fibroblast growth factor receptors (FGFRs) have been attractive drug targets for a variety of cancers, and in 2019 the FDA approved the first therapy targeted against FGFR3 for bladder cancer. Given the excitement around these new receptor tyrosine kinase and immune checkpoint targeted strategies, and the challenges they each may face on their own, emerging data suggest that combining these treatment options could lead to improved therapeutic outcomes. In this paper, we develop a mathematical model for FGFR3‐mediated tumor growth and use it to investigate the impact of the combined administration of a small molecule inhibitor of FGFR3 and a monoclonal antibody against the PD‐1/PD‐L1 immune checkpoint. The model is carefully calibrated and validated with experimental data before survival benefits, and dosing schedules are explored. Predictions of the model suggest that FGFR3 mutation reduces the effectiveness of anti‐PD‐L1 therapy, that there are regions of parameter space where each monotherapy can outperform the other, and that pretreatment with anti‐PD‐L1 therapy always results in greater tumor reduction even when anti‐FGFR3 therapy is the more effective monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied BioMath, LLC, Concord, Massachusetts, USA.
- Department of Mathematics, University of Michigan, Ann Arbor, Michigan, USA.
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Trachette L Jackson
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Okuneye, K., Bergman, D., Bloodworth, J. C., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2021). A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Computational and Systems Oncology. https://doi.org/10.1002/cso2.1019
Vancouver
Okuneye K, Bergman D, Bloodworth JC, Pearson AT, Sweis RF, Jackson TL. A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Computational and Systems Oncology. 2021. doi:10.1002/cso2.1019
BibTeX
@article{Okuneye2021,
author = {Okuneye, Kamaldeen and Bergman, Daniel and Bloodworth, Jeffrey C and Pearson, Alexander T and Sweis, Randy F and Jackson, Trachette L},
title = {A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer},
journal = {Computational and Systems Oncology},
year = {2021},
doi = {10.1002/cso2.1019}
}
EUVIMED